[Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].


Cutaneous follicular center B-cell lymphomas are indolent tumors characterized by the presence of neoplastic follicular center cells. They contain a mixture of centrocytes with a variable number of centroblasts. The tumor is usually treated by surgery or radiotherapy, although other treatments may be used such as interferon-alpha, chemotherapy, and biological agents (rituximab). Rituximab is a chimeric monoclonal anti-CD20 antibody that can be administered intravenously or intralesionally. We report the case of a 41-year-old man who consulted for violaceous nodular lesions in the left scapular region and who was diagnosed with cutaneous follicular center B-cell lymphoma after biopsy, laboratory tests, thoracic-abdominal-pelvic computed tomography, abdominal ultrasound, and bone marrow biopsy. It was decided to treat him with 30 mg of intralesional rituximab administered for 1 week (3 times) every month for 4 months. Complete response was obtained. We also review the published cases of cutaneous B-cell lymphoma treated with intralesional rituximab.

4 Figures and Tables

Cite this paper

@article{Gamo2008CutaneousFC, title={[Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].}, author={Reyes Gamo and Leticia Calzado and Fernando Javier Pinedo and J-L L{\'o}pez-Estebaranz}, journal={Actas dermo-sifiliográficas}, year={2008}, volume={99 4}, pages={291-6} }